跳至主要内容
临床试验/NCT00493480
NCT00493480已完成3 期

Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices

Hvidovre University Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2003年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
40
试验地点
1
主要终点
If carvedilol is better than propranolol in lowering portal pressure after 3 months of treatment

研究概览

简要总结

Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding. 20-40% of the patients do not respond to this treatment or have to discontinue the treatment because of side effects. The aim of this study is to evaluate if carvedilol (a combined alfa -beta blocker) has better efficacy and safety than propranolol in lowering the portal pressure in patients with cirrhosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cirrhosis
  • HVPG > 12 mmHg

排除标准

  • Respiratory disease that contradict endoscopy
  • Hepatic encephalopathy
  • Hepatorenal syndrome
  • COPD or Asthma
  • Treatment with vasoactive drugs within 1 week of inclusion
  • Heart disease that contradict treatment with beta-blocking agents
  • Pregnancy

研究组 & 干预措施

carvedilol

Active Comparator

干预措施: carvedilol (Drug)

propranolol

Active Comparator

Cirrhotic patients treated with propranolol

干预措施: propranolol (Drug)

结局指标

主要结局

If carvedilol is better than propranolol in lowering portal pressure after 3 months of treatment

时间窗: 3 months

次要结局

  • If the effect of a single dose of propranolol can predict the long term effect of propranolol or carvedilol(3 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验